Paper41316360
LncRNA LEF1-AS1 exerts a carcinogenic effect in breast cancer by accelerating proliferation, metastasis, and epithelial-mesenchymal transition.
Kong L and 3 others. Hereditas, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. LncRNA LEF1-AS1 exerts a carcinogenic effect in breast cancer by accelerating proliferation, metastasis, and epithelial-mesenchymal transition. Papers, record 41316360. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41316360
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LncRNA LEF1-AS1 exerts a carcinogenic effect in breast cancer by accelerating proliferation, metastasis, and epithelial-mesenchymal transition.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epithelial-Mesenchymal Transition | Major topic |
| Breast Neoplasms | Major topic |
| RNA, Long Noncoding | Major topic |
| Lymphoid Enhancer-Binding Factor 1 | Major topic |
| Carcinogenesis | Major topic |
| Humans | |
| Cell Proliferation | |
| Female | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Cell Movement | |
| MicroRNAs | |
| Neoplasm Metastasis | |
| Apoptosis |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40540857 | Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications. | Cancer Treat Rev | 2025 | https://conductscience.org/library/papers/40540857 | PubMed |
| 2 | 39261346 | LncRNA XIST/miR-455-3p/HOXC4 axis promotes breast cancer development by activating TGF-β/SMAD signaling pathway. | Funct Integr Genomics | 2024 | https://conductscience.org/library/papers/39261346 | PubMed |
| 3 | 32099465 | LncRNA LEF1-AS1 Promotes Ovarian Cancer Development Through Interacting with miR-1285-3p. | Cancer Manag Res | 2020 | https://conductscience.org/library/papers/32099465 | PubMed |
| 4 | 35371339 | lncRNA LEF1-AS1 Acts as a Novel Biomarker and Promotes Hypopharyngeal Squamous Cell Carcinoma Progression and Metastasis by Targeting the miR-221-5p/GJA1 Axis. | Dis Markers | 2022 | https://conductscience.org/library/papers/35371339 | PubMed |
| 5 | 27444227 | Non-coding RNAs as drug targets. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/27444227 | PubMed |
| 6 | 36276461 | A systems biology investigation of curcumin potency against TGF-β-induced EMT signaling in lung cancer. | 3 Biotech | 2022 | https://conductscience.org/library/papers/36276461 | PubMed |
| 7 | 35743249 | Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35743249 | PubMed |
| 8 | 31599448 | Upregulation of long noncoding RNA LEF1-AS1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma. | Eur Rev Med Pharmacol Sci | 2019 | https://conductscience.org/library/papers/31599448 | PubMed |
| 9 | 30147992 | Tomosynthesis-Guided Core Biopsy of the Breast: Why and How to Use it. | J Clin Imaging Sci | 2018 | https://conductscience.org/library/papers/30147992 | PubMed |
| 10 | 35796007 | Transcription factor KLF16 activates MAGT1 to regulate the tumorigenesis and progression of breast cancer. | Int J Mol Med | 2022 | https://conductscience.org/library/papers/35796007 | PubMed |
| 11 | 30734202 | LEF1-AS1 contributes to proliferation and invasion through regulating miR-544a/ FOXP1 axis in lung cancer. | Invest New Drugs | 2019 | https://conductscience.org/library/papers/30734202 | PubMed |
| 12 | 23237552 | On the origin of cancer metastasis. | Crit Rev Oncog | 2013 | https://conductscience.org/library/papers/23237552 | PubMed |
| 13 | 29516641 | Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. | J Cell Mol Med | 2018 | https://conductscience.org/library/papers/29516641 | PubMed |
| 14 | 35013579 | Non-coding RNAs as liquid biopsy biomarkers in cancer. | Br J Cancer | 2022 | https://conductscience.org/library/papers/35013579 | PubMed |
| 15 | 39323334 | Revealing the Molecular Signatures of miR-185-5p on Breast Cancer Cells Using Proteomic Analysis. | Protein Pept Lett | 2024 | https://conductscience.org/library/papers/39323334 | PubMed |
| 16 | 39323624 | Beyond the Genome: Deciphering the Role of MALAT1 in Breast Cancer Progression. | Curr Genomics | 2024 | https://conductscience.org/library/papers/39323624 | PubMed |
| 17 | 37666286 | miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer progression and metastasis: A focus on gastric and bladder cancers. | Cell Signal | 2023 | https://conductscience.org/library/papers/37666286 | PubMed |
| 18 | 33292271 | LncRNA LEF1-AS1 promotes metastasis of prostatic carcinoma via the Wnt/β-catenin pathway. | Cancer Cell Int | 2020 | https://conductscience.org/library/papers/33292271 | PubMed |
| 19 | 31536481 | Two Novel Long Noncoding RNAs - RP11-296E3.2 and LEF1-AS1can - Separately Serve as Diagnostic and Prognostic Bio-Markers of Metastasis in Colorectal Cancer. | Med Sci Monit | 2019 | https://conductscience.org/library/papers/31536481 | PubMed |
| 20 | 38284731 | Anticancer Properties of Baicalin against Breast Cancer and other Gynecological Cancers: Therapeutic Opportunities based on Underlying Mechanisms. | Curr Mol Pharmacol | 2024 | https://conductscience.org/library/papers/38284731 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| LEF1-AS1 | 641518 | PubTator's text mining | https://conductscience.org/library/genes/641518 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41316360
GET https://conductscience.org/api/papers/v1/41316360/references?page=2